Ann: Increased Scheme Consideration from Pfizer, page-295

It is also open to the Independent Expert to change their opinion at any time up to the date of the shareholder's meeting. There is every possibility that the Independent Expert may conclude that a successful data validation test materially increases the value of the company and the revised scheme is no longer in the best interests of shareholders.